SALT LAKE CITY, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its third quarter 2023 operating results on Wednesday, November 8, 2023, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.
Conference Call Details
The conference call can be accessed by dialing 800-225-9448 for U.S. participants, or 203-518-9708 for international participants, and referencing conference ID “HCAT Q323.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Health Catalyst
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.
Health Catalyst Investor Relations Contact:
Adam Brown
Senior Vice President, Investor Relations and FP&A
+1 (855)-309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.
Health Catalyst Media Contact:
Tarah Neujahr Bryan
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$7.70 |
Daily Change: | -0.34 -4.23 |
Daily Volume: | 376,672 |
Market Cap: | US$465.620M |
August 27, 2024 August 08, 2024 August 08, 2024 August 07, 2024 May 21, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB